Vigeo Therapeutics

Vigeo Therapeutics

  • Founded: 2011
  • Location: Cambridge, MA
  • Employee range: 1 - 10
  • Clinical stage: Clin1/Clin2
  • Therapy area: Glioblastoma
  • Drug types: ONC
  • Lead product: VT1021
  • Product link:

job board

Short description:

Biologics for Cancer

Drug notes:

Also Clin2 pancreatic ductal adenocarcinoma, Clin2 oncology; VT200X RD oncology; VT300X RD oncology; VT400X/VT500X RD oncology

Long description:

Vigeo Therapeutics is building a therapeutic pipeline aimed at reinvigorating the immune system for the treatment of immunological and inflammatory disorders, such as neurodegenerative disease and cancer. They are harnessing the power of cytokine modulation, specifically targeting the signaling pathways involved in immune dysregulation. Vigeo Therapeutics employs advanced biologics and small molecule therapies designed to selectively modulate immune responses, aiming to achieve therapeutic efficacy while minimizing adverse effects. Through rigorous scientific research and innovative drug development strategies, Vigeo Therapeutics seeks to address unmet medical needs and improve the lives of patients affected by these complex and challenging conditions.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy